There appeared to be little interest among FDA advisory committee members to rush adjustments to the labeling for Pfizer Inc.’s smoking cessation drug Chantix, especially with a clinical trial about to be completed that may answer the question.
The result seems to be a negative for Pfizer, which had submitted a supplemental application to make several labeling changes for Chantix (varenicline), a product